What is label or ink migration in packaging:

Label migration refers to the transfer of chemicals—particularly inks, adhesives, and coatings—from printed packaging materials into the pharmaceutical product. This is a concern when the product is stored in direct contact with printed surfaces, such as blisters, pouches, or sachets without internal barriers.

Migrated substances can contaminate the formulation, alter its appearance or odor, and potentially create toxicity or efficacy risks.

Why migration testing is crucial for stability:

During long-term stability, especially under elevated temperature or humidity, label constituents may migrate at an accelerated rate. Without prior testing, companies risk discovering this issue late in development—forcing costly packaging changes or product recalls.

This tip emphasizes proactive compatibility assessments during packaging qualification to ensure product integrity throughout shelf life.

Real-world consequences of overlooking label migration:

Undetected migration has led to regulatory alerts, market withdrawals, and damaged reputations in pharmaceutical and nutraceutical sectors. Migration-related failures have included solvent leaching into oral solutions, discoloration in tablets, or adhesive odors permeating through sachets.

Regulatory and Technical Context:

ICH, FDA, and EU expectations:

ICH Q1A(R2) and Q3C highlight the need to assess the compatibility of drug products with their packaging. EU GMP Annex 9, FDA container closure guidance, and EMA packaging material guidelines specifically mandate migration assessments when printed components contact dosage forms.

Agencies expect label migration risks to be addressed in CTD Module 3.2.P.7 (Container Closure System), supported by studies or justification.

Migration-related compliance risks:

During regulatory inspections, auditors review whether migration was evaluated for contact-sensitive packaging. Absence of such data—especially for low-permeability plastics or solvent-based inks—can result in compliance observations or submission deficiencies.

Migration is also increasingly scrutinized in pediatric formulations, inhalation products, and high-exposure dosage forms.

Best Practices and Implementation:

Assess product-packaging contact risk:

Identify all instances where the product is in direct contact with printed surfaces—especially in unit-dose forms, powders in sachets, or semi-solids in printed tubes. Consider the presence of volatile solvents, hydrophilic excipients, or permeable matrices that may accelerate migration.

Categorize packaging types by risk level and prioritize high-risk configurations for formal migration studies.

Design and conduct migration studies:

Place placebo or representative product samples in contact with printed packaging under ICH stability conditions (e.g., 25°C/60% RH or 40°C/75% RH). Analyze for potential migrants such as ink components, plasticizers, or adhesives using GC-MS, LC-MS, or headspace analysis techniques.

Compare results against toxicological thresholds and determine whether migration is within acceptable safety limits.

Validate packaging materials and establish controls:

If migration is detected but within safe limits, include data in your CTD and define usage duration and storage conditions accordingly. If excessive migration occurs, switch to barrier layers (e.g., unprinted liners or foil lamination) or reformulate ink systems.

Ensure all packaging vendors provide toxicological clearance and material safety certificates for inks, adhesives, and substrates used in pharmaceutical contact layers.